NSE List Price : ₹

subscription

Category	Times
QIBs	4.15x
HNIs	5.26x
Retail	3.69x
Total : 4.16x

IPO Market Lot(s) Distribution

Application	Lot Size	Shares	Amount
Retail Minimum	2	800	₹274,400
Retail Maximum	2	800	₹274,400
S-HNI Minimum	3	1,200	₹411,600
S-HNI Maximum	7	2,800	₹960,400
B-HNI Minimum	8	3,200	₹1,097,600

About the Company

Established in 2013, Q-Line Biotech operates in the healthcare and diagnostics sector. The company specializes in the manufacturing and distribution of In-Vitro Diagnostic (IVD) products, diagnostic medical equipment, reagents, rapid testing kits, and pathology instruments. It is recognized for delivering reliable products and services at cost-effective prices.

Q-Line Biotech possesses more than 15 years of industry expertise in diagnostics and has catered to over 150 domestic and international clients. In addition, the company has around 12 years of experience in product development and manufacturing. Its portfolio covers haematology, point-of-care (POC) testing, clinical chemistry, molecular diagnostics, rapid testing solutions, ELISA, and specialized diagnostic products.

Company Financial Report

_{Amount ₹ in Crores}

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Company Promoter

Saurabh Garg

Amita Garg

Ayush Garg

Ajay Kumar Mahanty

Abhay Agrawal

Know before investing

• • Strengths

  Robust Manufacturing and R&D Strength: The company possesses strong research, development, and reverse engineering capabilities backed by a team of 23 scientists and engineers, along with three manufacturing units dedicated to maintaining quality and driving innovation.

  Experienced Leadership Team: The company is managed by promoters and senior executives who possess significant experience in the diagnostic and IVD sector, covering areas such as manufacturing, research & development, quality assurance, sales, and operations.

• • Risks

  Regulatory and Compliance Risk: The company functions in a strictly regulated sector. Any non-compliance with manufacturing standards, clinical validation processes, testing norms, or regulatory guidelines could result in penalties, product recalls, or interruptions in business operations.

  Quality Control and Manufacturing Risk: Any shortcomings in product quality, manufacturing procedures, or quality assurance standards may lead to loss of customers, legal claims, regulatory penalties, and harm to the company’s reputation.

Objects of the Issue & Utilisation of proceeds

To meet Working Capital requirements.

Repayment of certain borrowing availed by the Company, in part or full.

General Corporate Purpose.

Company  Address

Q-Line Biotech Ltd.
298-281,
Transport Nagar,
Kanpur Road Adjacent Transport Nagar Metro Station
Lucknow, Uttar Pradesh, 226012
Phone: +91 522-2435570
Email: compliance@qlinebiotech.com
Website: https://qlinebiotech.com/

IPO Registrar

Purva Sharegistry (India) Pvt.Limited.
Phone: +91-022-23018261/ 23016761
Email: support@purvashare.com
Website: https://www.purvashare.com/investor-service/ipo-query

IPO Review

May Apply